<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77408">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02123745</url>
  </required_header>
  <id_info>
    <org_study_id>IVW400CS-06</org_study_id>
    <nct_id>NCT02123745</nct_id>
  </id_info>
  <brief_title>ivWatch Model 400: Device Validation for Infiltrated Tissues</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>ivWatch, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ivWatch, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm trial consisting of 70 adult volunteers to assess the safety and efficacy of
      the ivWatch Model 400 when observing infiltrated tissues at common sites for peripheral IV
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Red Notification Sensitivity to Infiltrated Tissues</measure>
    <time_frame>After each participant has been infiltrated, an expected average of 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>The ratio of the number of infiltrated IV sites where the ivWatch Model 400 device issued a red notification to the total number of infiltrated IV sites in the study. All infiltrations were limited to 10 mL of isotonic saline solution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yellow Notification Sensitivity to Infiltrated Tissues</measure>
    <time_frame>After each participant has been infiltrated, an expected average of 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>The ratio of the number of infiltrated IV sites where the ivWatch Model 400 device issued a yellow notification to the total number of infiltrated IV sites in the study. All infiltrations were limited to 10 mL of isotonic saline solution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infiltrated Volume when Red Notification Issued</measure>
    <time_frame>After each participant has been infiltrated, an expected average of 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>The amount of infiltrated isotonic saline solution when the red notification was issued by the ivWatch Model 400 device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infiltrated Volume when Yellow Notification Issued</measure>
    <time_frame>After each participant has been infiltrated, an expected average of 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>The amount of infiltrated isotonic saline solution when the yellow notification was issued by the ivWatch Model 400 device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant Skin Irritation or Disruption to Skin Integrity</measure>
    <time_frame>After each participant has been infiltrated, an expected average of 1 hour</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of IV sites that indicated significant skin irritation or disruption to skin integrity assessed at the end of the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Infiltration of Peripheral IV Therapy</condition>
  <arm_group>
    <arm_group_label>Infiltrated Tissue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The ivWatch Model 400</intervention_name>
    <description>The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.</description>
    <arm_group_label>Infiltrated Tissue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Pass health screen by clinician

          -  18 years or older

        Exclusion Criteria:

          -  Fail health screen
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ivWatch, LLC</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infiltration</keyword>
  <keyword>extravasation</keyword>
  <keyword>peripheral intravenous therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
